Everything below concerns Reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
The second concern would be that some of the heavy metals that could be released can have some level of toxicity to not only organisms inhabiting that area but also organisms passing through the mining site area. The concerns surrounding increased sediment release are mainly related to the other two mining waste processes, side cast sediment and seafloor sediment disturbance. The main environmental concern would be the smothering of organisms below as a result of redistributing large amounts of sediment to other areas on the seafloor, which could potentially threaten the population of organisms inhabiting the area. Redistribution of large quantities of sediment can also affect the feeding and gas exchange processes between organisms, posing a serious threat to the population. Finally, these processes can also increase the sedimentation rate on the seafloor, resulting in a predicted minimum of 500 m per every 1–10 km. A large amount of work is currently being engaged in by both of the above-mentioned companies to ensure that the potential environmental impacts of seafloor mining are well understood and control measures are implemented before exploitation commences. However, this process has been arguably hindered by the disproportionate distribution of research effort among vent ecosystems; the best studied and understood hydrothermal vent ecosystems are not representative of those targeted for mining. Attempts have been made in the past to exploit minerals from the seafloor.
As of the 2020 census, there were 467,665 people, 188,412 households, and 104,848 families residing in the city. In the American Community Survey of 2019, the city of Raleigh's population was estimated at 474,708; an earlier estimate determined the population at 474,069. At the 2000 census, there were 276,093 persons (July 2008 estimate was 380,173) and 61,371 families residing in Raleigh. The population density was 2,409.2 people per square mile (930.2 people/km2). There were 120,699 housing units at an average density of 1,053.2 per square mile (406.6/km2). There were 112,608 households in the city in 2000, of which 26.5% included children below the age of 18, 39.5% were composed of married couples living together, 11.4% reported a female householder with no husband present, and 45.5% classified themselves as nonfamily. Unmarried partners were present in 2.2% of households. In addition, 33.1% of all households were composed of individuals living alone, of which 6.2% was someone 65 years of age or older. The average household size in Raleigh was 2.30 persons, and the average family size was 2.97 persons. Raleigh's population in 2000 was evenly distributed with 20.9% below the age of 18, 15.9% aged 18 to 24, 36.6% from 25 to 44, and 18.4% from 45 to 64. An estimated 8.3% of the population was 65 years of age or older, and the median age was 31 years. For every 100 females, there were 98.0 males; for every 100 females aged 18 or older, there were 96.6 males aged 18 or older.
=== Magnetic === In 2015 researchers announced a graphene-based magnetic sensor 100 times more sensitive than an equivalent device based on silicon (7,000 volts per amp-tesla). The sensor substrate was hexagonal boron nitride. The sensors were based on the Hall effect, in which a magnetic field induces a Lorentz force on moving electric charge carriers, leading to deflection and a measurable Hall voltage. In the worst case graphene roughly matched a best case silicon design. In the best case graphene required lower source current and power requirements.
1,4-Butanediol, also called butane-1,4-diol (other names include 1,4-B, BD, dose, BDO, and 1,4-BD), is a primary alcohol and an organic compound with the formula HOCH2CH2CH2CH2OH. It is a colorless viscous liquid first synthesized in 1890 via acidic hydrolysis of N,N'-dinitro-1,4-butanediamine by Dutch chemist Pieter Johannes Dekkers, who called it "tetramethylene glycol".
Sources: en.wikipedia.org
Isobutyryl-coenzyme A is a necessary cofactor required for Polyketide synthase (PKS) enzyme(s), to catalyze the a,b-dehydrogenation of acyl-CoA esters to make many natural products via Polyketide synthase (PKS) assembly lines, as well as PKS-NRPS hybrid assembly lines. The resulting products comprise antibiotics and other bioactive molecules. Notably, isobutyryl-coenzyme A is also an intermediate in the metabolism of the amino acid valine, and it is structurally similar to intermediates in the catabolism of other small amino acids. Defective Isobutyryl-coenzyme A, produced by the body, often results in a metabolic disease.
1993/1789) Criminal Justice Act 1988 (Designated Countries and Territories) (Amendment) Order 1993 (S.I. 1993/1790) Criminal Justice (International Co-operation) Act 1990 (Enforcement of Overseas Forfeiture Orders) (Amendment) Order 1993 (S.I. 1993/1791) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) Order 1993 (S.I. 1993/1792) Haiti (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/1793) Haiti (United Nations Sanctions)(Isle of Man) Order 1993 (S.I. 1993/1794) Hong Kong (British Nationality) (Amendment) Order 1993 (S.I. 1993/1795) Immigration (Guernsey) Order 1993 (S.I. 1993/1796) Immigration (Jersey) Order 1993 (S.I. 1993/1797) Iraq (United Nations) (Sequestration of Assets) (Guernsey) Order 1993 (S.I. 1993/1798) Iraq (United Nations) (Sequestration of Assets) (Jersey) Order 1993 (S.I. 1993/1799)
== Society and culture == Melarsoprol is produced by Sanofi and under an agreement with the WHO, it donates melarsoprol to countries where the disease is common. Melarsoprol was used to treat a patient with second-stage African trypanosomiasis on season 1 episode 7 "Fidelity" of the medical drama House MD.
Sources: en.wikipedia.org
There are several steps in the brewing process, which may include malting, mashing, lautering, boiling, fermenting, conditioning, filtering, and packaging. The brewing equipment needed to make beer has grown more sophisticated over time, and now covers most aspects of the brewing process. Malting is the process where barley grain is made ready for brewing. Malting is broken down into three steps in order to help to release the starches in the barley. First, during steeping, the grain is added to a vat with water and allowed to soak for approximately 40 hours. During germination, the grain is spread out on the floor of the germination room for around 5 days. The final part of malting is kilning when the malt goes through a very high temperature drying in a kiln; with gradual temperature increase over several hours. When kilning is complete, the grains are now termed malt, and they will be milled or crushed to break apart the kernels and expose the endosperm, which contains the majority of the carbohydrates and sugars; this makes it easier to extract the sugars during mashing. Mashing converts the starches released during the malting stage into sugars that can be fermented. The milled grain is mixed with hot water in a large vessel known as a mash tun. In this vessel, the grain and water are mixed together to create a cereal mash. During the mash, naturally occurring enzymes present in the malt convert the starches (long chain carbohydrates) in the grain into smaller molecules or simple sugars (mono-, di-, and tri-saccharides).
Effective vaccines for Haemophilus influenzae serotype b have been available since the early 1990s, and are recommended for children under age 5 and asplenic patients. The World Health Organization recommends a pentavalent vaccine, combining vaccines against diphtheria, tetanus, pertussis, hepatitis B and Hib. There is not yet sufficient evidence on how effective this pentavalent vaccine is in relation to the individual vaccines. Hib vaccines cost about seven times the total cost of vaccines against measles, polio, tuberculosis, diphtheria, tetanus, and pertussis. Consequently, whereas 92% of the populations of developed countries, 94% for European countries, were vaccinated against Hib as of 2023, vaccination coverage was 77% globally, and only 33% for people living in the western pacific region. The Hib vaccines do not provide cross-protection to any other H. influenzae serotypes like Hia, Hic, Hid, Hie or Hif. An oral vaccination has been developed for non-typeable H. influenzae (NTHi) for patients with chronic bronchitis, but it has not shown to be effective in reducing the number and severity of COPD exacerbations. However, there is no effective vaccine for the other types of capsulated H. influenzae or NTHi. Vaccines that target unencapsulated H. influenzae serotypes are in development. By 2026, following the decline of vaccinations in the United States, Hib was confirmed to be making a comeback in the country.
In dental anatomy, the apical foramen, literally translated "small opening of the apex," is the tooth's natural opening, found at the root's very tip—that is, the root apex — whereby an artery, vein, and nerve enter the tooth and commingle with the tooth's internal soft tissue, called pulp. Additionally, the apical foramen is the point where the pulp meets the periodontal tissues, the connective tissues that surround and support the tooth. The foramen is located 0.5mm to 1.5mm from the apex of the tooth. Each tooth has an apical foramen.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.